|Bid||7.29 x 1100|
|Ask||7.30 x 2200|
|Day's Range||7.10 - 7.72|
|52 Week Range||3.60 - 17.60|
|Beta (3Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Boston, MA, based Investment company SV Life Sciences Advisers, LLC buys Catabasis Pharmaceuticals Inc, sells KalVista Pharmaceuticals Inc, Avrobio Inc during the 3-months ended 2019Q1, according to the ...
Anyone researching Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of...
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So take a moment to sympathizeRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 5) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Array ...
Jill Milne has been the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) since 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Catabasis Pharmaceuticals, Inc. (CATB) has been struggling lately, but the selling pressure may be coming to an end soon.
If you’re interested in Catabasis Pharmaceuticals Inc (NASDAQ:CATB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 8 cents. The company's shares closed at 65 cents. A year ago, they were trading at $1.82. _____ This story was generated ...
A Catabasis spokesperson said the company ended its laboratory work earlier this year as it focuses on a single drug.